Netakimab manufacturers
- Netakimab
-
- $137.00
-
2026-08-16
- CAS:1796570-08-5
- Purity: 97.57% (SEC-HPLC)
- Supply Ability: 10g
|
| | Netakimab Basic information |
| Product Name: | Netakimab | | Synonyms: | Netakimab;Research Grade Netakimab(DHH28805);Research Grade Netakimab;Netakimab (anti-IL-17A) | | CAS: | 1796570-08-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Netakimab Structure]() |
| | Netakimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Netakimab Usage And Synthesis |
| Uses | Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis[1][2]. | | References | [1] Puig L, et al. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatol Ther (Heidelb). 2021 Aug;11(4):1319-1332. DOI:10.1007/s13555-021-00554-4
[2] Erdes S, et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol. 2020 Jan-Feb;38(1):27-34. Epub 2019 Apr 16. PMID:31025924 |
| | Netakimab Preparation Products And Raw materials |
|